文献速递乳房整形与再造创面修复

脂质体布比卡因与盐酸布比卡因腹横肌平面阻滞在腹部自体显微血管乳房再造术后的镇痛效果:前瞻性单盲随机对照试验

The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial.
PubMed 文献 · Plast Reconstr Surg · 2019-01-01

该前瞻性单盲随机对照试验纳入44例腹部自体显微血管乳房再造患者,比较腹横肌平面阻滞使用266 mg脂质体布比卡因与75 mg常规布比卡因的镇痛效果。在加速康复方案下,两组阿片类药物总消耗量、恢复质量-15评分、疼痛评分及住院时间均无显著差异。结论认为单次注射脂质体布比卡因相比常规布比卡因无优势。

要点

  • 在加速康复方案下,脂质体布比卡因腹横肌平面阻滞未减少阿片类药物消耗。
  • 脂质体布比卡因未改善恢复质量、疼痛评分或缩短住院时间。
  • 单次腹横肌平面阻滞中脂质体布比卡因相比常规布比卡因无临床优势。

核心结论

  • 在完善的加速康复外科方案下,腹部自体显微血管乳房再造术后单次腹横肌平面阻滞使用脂质体布比卡因相比常规布比卡因不具优势。

研究设计与样本

  • 前瞻性、单盲、随机对照试验,纳入2016年6月至2018年2月由单一外科医生完成的44例腹部自体乳房再造患者。
  • 患者随机接受266 mg脂质体布比卡因或75 mg常规布比卡因行腹横肌平面阻滞,术后均按加速康复方案管理。

主要发现

  • 44例中22例接受常规布比卡因、22例接受脂质体布比卡因腹横肌平面阻滞。
  • 阿片类药物总消耗量无差异(p=0.98)。
  • 恢复质量-15评分无差异(p=0.72)。
  • 疼痛评分无差异(p=0.39)。
  • 住院时间无差异(p=0.20)。

临床怎么用

  • 在已有加速康复方案的中心,腹部自体显微血管乳房再造术后腹横肌平面阻滞可选用常规布比卡因,无需常规使用脂质体布比卡因。

局限性

  • 单中心、单一外科医生研究,样本量44例。
  • 研究在完善的加速康复方案背景下进行,结果可能受该方案影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative pain control after abdominally based autologous microvascular breast reconstruction is critical to functional recovery, patient satisfaction, and early discharge. The transversus abdominis plane block using 0.25% bupivacaine hydrochloride has been shown to be effective, but it is limited by a short duration of effect. Liposomal bupivacaine is a recently U.S. Food and Drug Administration-approved preparation of bupivacaine that can provide up to 72 hours of pain relief. The purpose of this randomized, controlled trial was to compare the analgesic efficacy of liposomal bupivacaine and conventional bupivacaine. METHODS: This study was a prospective, single-blind, randomized, controlled trial of 44 patients undergoing abdominally based autologous breast reconstruction between June of 2016 and February of 2018 performed by a single surgeon. Each patient was randomized to receive either 266 mg of liposomal bupivacaine or 75 mg of conventional bupivacaine to the transversus abdominis plane at the conclusion of the reconstruction procedure. All patients were managed postoperatively according to an enhanced recovery protocol. RESULTS: In our study of 44 patients, 22 patients received a transversus abdominis plane block with conventional bupivacaine and 22 patients received liposomal bupivacaine. There were no significant differences with regard to any outcome measure. No differences were found in total opioid consumption (p = 0.98), Quality of Recovery-15 scores (p = 0.72), pain scores (p = 0.39), or length of stay (p = 0.20). CONCLUSION: In the setting of a robust enhanced recovery after surgery protocol, liposomal bupivacaine does not confer advantages over conventional bupivacaine when used as single injections in transversus abdominis plane blocks after abdominally based microvascular breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Ha AY, Keane G, Parikh R, et al. The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial. Plast Reconstr Surg. 2019. PMID: 31246796. doi:10.1097/PRS.0000000000005698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。